Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Assembly BiosciencesASMB -3.50%32 Cash-to-Debt is 90.97 as of Mar. 2026, which is 159% above its 10-year median of 35.08. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,401 Biotechnology companies, Assembly Biosciences ranks better than 75.87% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Assembly Biosciences's cash to debt ratio for the quarter that ended in Mar. 2026 was 90.97.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Assembly Biosciencescould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Assembly Biosciences's Cash-to-Debt or its related term are showing as below:
ASMB'
s Cash-to-Debt Range Over the Past 10 Years
Min: 12.03 Med: 35.08 Max: No Debt
Current: 90.97
During the past 13 years, Assembly Biosciences's highest Cash to Debt Ratio was No Debt. The lowest was 12.03. And the median was 35.08.
ASMB's Cash-to-Debt is ranked better than 75.87% of 1401
companies
in the Biotechnology industry
Industry Median: 6.56
vs ASMB: 90.97
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Assembly Biosciences Cash-to-Debt Related Terms
Assembly Biosciences Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Assembly Biosciences's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Assembly Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Assembly Biosciences Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Assembly Biosciences's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Assembly Biosciences's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Assembly Biosciences (ASMB) has a Cash-to-Debt of 90.97 as of Mar. 2026. This is 159% above median its historical median of 35.08. Over the past decade, Assembly Biosciences' Cash-to-Debt has ranged from 12.03 to 10,000.00. According to the industry distribution chart, Assembly Biosciences ranks #338 out of 1401 companies in the Biotechnology industry, placing it in the top 24.1%.
Is Assembly Biosciences' Cash-to-Debt too high?
Assembly Biosciences' current Cash-to-Debt of 90.97 is 159% above median its 10-year median of 35.08. Over the past 10 years, this metric has ranged from a low of 12.03 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.56. Assembly Biosciences' value of 90.97 is 1286.7% above this industry median. Based on the distribution chart, Assembly Biosciences ranks #338 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Cash-to-Debt compare to ZURA and ARVN?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #338 out of 1401 companies for Cash-to-Debt. This places Assembly Biosciences in the top 24% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 6.56. Assembly Biosciences' value of 90.97 is 1286.7% above this benchmark. Historically, Assembly Biosciences' own Cash-to-Debt has ranged from 12.03 to 10,000.00 over the past decade. While the company's 10-year median is 35.08 vs. the industry median of 6.56, Assembly Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.56, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Assembly Biosciences's current Cash-to-Debt of 90.97 is 1286.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Assembly Biosciences's current Cash-to-Debt is 90.97, which is 159% above median its own 10-year median of 35.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Cash-to-Debt of 90.97. The current Cash-to-Debt is 90.97, which is 159% above median its 10-year median of 35.08 and 1286.7% above the Biotechnology industry median of 6.56. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Cash-to-Debt is 90.97 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score
Get the complete analysis for ASMB
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASMB has been successfully added to your 
